Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to Treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day

Arthritis Care and Research

Volumn 65, Issue 5, 2013, Pages 729-736

  Pincus, Theodore ^a   Sokka, Tuulikki ^b   Castrejõn, Isabel ^a   Cutolo, Maurizio ^c  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISONE;

ARTICLE; CATARACT; DIABETES MELLITUS; DRUG EFFICACY; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIDE EFFECT; SKIN BRUISING; TREATMENT DURATION; WEIGHT GAIN;

ACADEMIC MEDICAL CENTERS; AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PREDNISONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876707866     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21899     Document Type: Article

References (49)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF,. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181-97.
2. Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959; 18: 173-88.
3. Bollet AJ, Black R, Bunim JJ,. Major undesirable side-effects resulting from prednisolone and prednisone. JAMA 1955; 158: 459-63.
4. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK,. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
5. Pincus T, Brooks RH, Callahan LF,. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
6. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
7. Caplan L, Wolfe F, Russell AS, Michaud K,. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34: 696-705.
8. Wei L, MacDonald TM, Walker BR,. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-70.
9. Hoffmeister RT,. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75 Suppl: 69-73.
10. Sokka T, Pincus T,. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; 47: 1543-7.
11. De Andrade JR, McCormick JN, Hill AG,. Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 1964; 23: 158-62.
12. Harris ED Jr, Emkey RD, Nichols JE, Newberg A,. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10: 713-21.
13. Kirwan JR,. The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6.
14. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
15. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, for the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568-73.
16. Van Everdingen AA, Jacobs JW, van Reesema DR, Bijlsma JW,. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002; 136: 1-12.
17. Wassenberg S, Rau R, Steinfeld P, Zeidler H, for the Low-Dose Prednisolone Therapy Study Group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-80.
18. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I, for the BARFOT Study Group. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70.
19. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Hantzschel H, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol 2008; 35: 979-85.
20. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156: 329-39.
21. Pincus T, Swearingen CJ, Luta G, Sokka T,. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715-20.
22. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S,. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996; 39: 1818-25.
23. Gotzsche PC, Johansen HK,. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316: 811-8.
24. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-4.
25. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Hetland ML, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66: 1491-6.
26. Danowski TS, Bonessi JV, Sabeh G, Sutton RD, Webster MW Jr, Sarver ME,. Probabilities of pituitary-adrenal responsiveness after steroid therapy. Ann Intern Med 1964; 61: 11-26.
27. Wood JB, Frankland AW, James VH, Landon J,. A rapid test of adrenocortical function. Lancet 1965; 1: 243-5.
28. Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O,. Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967; 26: 18-25.
29. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG,. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95: 258-64.
30. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-24.
31. Pincus T, Castrejon I, Sokka T,. Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years [review]. Clin Exp Rheumatol 2011; 29 Suppl: S130-8.
32. Pincus T, Stein CM, Wolfe F,. "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 591-6.
33. Pincus T, Sokka T, Stein CM,. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002; 136: 76-8.
34. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
35. Pincus T, Sokka T, Kautiainen H,. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol 2005; 32: 1432-9.
36. Felson DT,. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 531-4.
37. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R,. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47: 345-9.
38. Pincus T, Swearingen CJ, Bergman M, Yazici Y,. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008; 35: 2136-47.
39. Pincus T, Sokka T, Kautiainen H,. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-19.
40. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data [review]. Ann Rheum Dis 2006; 65: 285-93.
41. Pincus T, Sokka T,. Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am 2004; 30: 701-4.
42. Pincus T, Tugwell P,. Shouldn't standard rheumatology clinical care be "evidence-based" rather than "eminence-based," "eloquence-based" or "elegance-based"? J Rheumatol 2007; 34: 1-4.
43. Oxford Centre for Evidence-Based Medicine, OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. 2011. URL: http://www.cebm.net/index.aspx?o=5653.
44. Silman A, Davies P, Currey HL, Evans SJ,. Is rheumatoid arthritis becoming less severe? J Chronic Dis 1983; 36: 891-7.
45. Pincus T, Marcum SB, Callahan LF,. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
46. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of TNF blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006; 33: 2433-9.
47. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 506-14.
48. Pincus T, Wolfe F,. An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. J Rheumatol 2000; 27: 2727-30.
49. Pincus T,. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis 2009; 67: 254-66.